ExpreS2ion Biotechnologies – Nipah-vaccine project illustrates strength of platform and how the company can move on from the lost Covid-19 opportunity
On Thursday, we held an event with Expre2sion Biotechnologies following the announcement of a new exciting Nipah-vaccine project. At the event CEO Bent Frandsen presented the company's ExpreS2-platform and Adaptvac’s VLP technology. This unique technology platform is used for several projects in the company’s broad pipeline. In contrast to many other Life Science companies in their developing phase, ExpreS2ion Biotechnologies has already obtained a validation of its technology in connection with the completion of ABNCov2 phase 3 trial with Bavarian Nordic.
The unique technology platform also forms the basis for the recently announced Nipah virus project. It also includes the clinical team and partners. The Nipah-vaccine project is fully funded up to and including Phase 1. WHO characterizes the Nipah-disease as an extremely serious disease. It is hosted by bats and can be transmitted from bats to humans in which case it has a fatality rate of 40 to 75% with epidemic character and where there is currently no treatment. With the WHO label on the disease, a vaccine has a lot of focus from both the public and private markets. It also involves the risk of Nipah-virus being used in connection with bioterrorism which means many countries will consider building a strategic stock of vaccine once available. Generally, Expre2sion Biotechnologies’ commercialization strategy is to find a partner or finance a phase 2 development with its own funds or non-dilutive funding.
Listen to the interview here: Expre2sion Biotechnologies
Disclaimer: HC Andersen Capital receives payment from Expre2sion Biotechnologies for a DigitalIR/Corporate Visibility agreement.
ExpreS2ion Biotech Holding
ExpreS2ion er en biotekvirksomhed med base i Danmark, men børsnoteret i Sverige. Virksomheden udvikler en portefølje af vacciner mod sygdomme som COVID-19, influenza og brystkræft gennem brugen af dets cellebaserede ekspressionssystem, ExpreS2, som er anerkendt for at håndtere protein udfordringer. ExpreS2ion har udviklet Expres2, som er en teknologiplatform til effektiv og hurtig ikke-klinisk udvikling og produktion af komplekse proteiner til nye vacciner og diagnostik. På nuværende tidspunkt er selskabets primære produkt corona-vaccinekandidaten, ABNCoV2 som er i fase 2, udviklet sammen med sin partner, AdaptVac, hvoraf ExpreS2ion ejer 34%. Vaccinekandidatens licensret tilhører Bavarian Nordic som har globale kommercialiseringsrettigheder og ansvar for yderligere klinisk udvikling af vaccinen.
Read more on company page